drugset / Trial / NCT06941376
Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis
Non-randomizedCrossoverOpen-labelTreatment
Summary
Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
Timeline
- Start
- 2025-11-11
- Primary completion
- 2027-07
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Azathioprine | Small molecule | 2 mg/kg | — |
| Subject | Azathioprine | Small molecule | 3 mg/kg | — |
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Methotrexate | Small molecule | 20 mg | Oral |
| Subject | Tocilizumab | Monoclonal antibody | 4 mg/kg | Subcutaneous |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Subcutaneous |
| Subject | Tocilizumab | Monoclonal antibody | 162 mg | Subcutaneous |